Med-Design cannot pinpoint share price drop trigger?:
This article was originally published in Clinica
Executive Summary
Med-Design, which is currently negotiating licences for its retractable safety needle technology, says it is unaware of any fundamental reason for the recent decline in the price of its shares. The US company says it has had a positive response from potential licensees and that the sale of its shares appears to be due to "technical conditions associated with the liquidation of margin debt". Around one million needlestick accidents occur in the US each year, according to the American Hospital Association.
You may also be interested in...
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.